The Prevalence and Factors Associated with Drug-induced Hepatitis in HIV-positive Tuberculosis Patients
DOI:
https://doi.org/10.24871/132201280-85Abstract
Introduction: Tuberculosis (TB) have demonstrated a global increase since 1990 along with the increase of world’s population and the transmission of human immunodeficiency virus (HIV). Anti- tuberculosis drugs are very effective, but it may cause drug-induced hepatitis (DIH). The aim of this study was to assess the prevalence and association of several risk factos with the occurence of drug-induced hepatitis in HIV-positive tuberculosis patients.Method: We conducted a retrospective case-control study based on medical records of HIV-positive TB patients who seek medical attention to HIV Referral Center at Cipto Mangunkusumo Hospital between July 2008 and December 2010. Overall, we enrolled 168 medical records with 42 cases and 126 controls. Chi-square and logistic regression test analysis were conducted for analyzing risk factors of drug-induced hepatitis in HIV-positive tuberculosis patients.
Results: Drug-induced hepatitis were found in 42 (8.04%) patients.The prevalence of DIH was highest among 35 (25.2%) male patients, aged < 35 years old in 32 (26.0%) patients, with albumin level < 3.5 g% in 10 (11.2%) patients, body mass index (BMI) < 18.5 kg/m2 in 14 (18.4%) patients, CD4+ count < 100 cells/mm3 in 29 (24.4%) patients, and those who received rifampicin (R), isoniazid (H), and pirazinamid (Z) regiments for their anti-tuberculosis drugs 24 (31.2%) patients. No risk factors were found to have statistically significant association with DIH.
Conclusion: The prevalence of DIH is quite high. Although no risk factor was found statistically significant, but evaluation and liver biochemical examination should be carried out regularly in patients with DIH risk factors.
Keywords: drug-induced hepatitis, tuberculosis, human immunodeficiency virus
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).










